Genzyme Corp

Genzyme — Ilex Oncology — Merger or Acquisition (March 2004)

21 slides from Genzyme's merger presentation, Mar 1, 2004

  1. Slide 1: ILEX Oncology, Inc. – Hope into Reality

    ILEX™ Oncology, Inc. Saale aaENESEIErenml HOPE INTO REALITY? March 2004

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements 9 ‘These presentations contain fomardlecking statements, including vthout imitation statements regarding sthe potental business combination betueen Genzyme and ILEX and the benefits therecf sfinandial guidance; “projected plans and ming for product development and regulato

  3. Slide 3: Genzyme – Additional Information and Participants Notice

    genzyme This presentation is not a substitute for the prospectus/proxy statement Genzyme and ILEX intend to file with the U.S. Securities and Exchange Commission. Investors are urged ta read that document when it becomes available, because it will contain important information about Genzyme, ILEX, t

  4. Slide 4: Genzyme marketed products and programs

    genzymne Cerezyme® Fabrazyme® Aldurazyme® Myozyme? Niemann Pick Renagel® Sevelamer-CKD Renal fibrosis PKD ‘Synvisc® Carticel® Synvisc It Marketed Products Transplant & Immune Disease Oncology! Endocrinology Thymoglobultin Thyrogen® Lymphoglobulin® Cancer Programs RDP.68 Dx-88 Anti-TGFB antibodies Ms

  5. Slide 5: Worldwide Cancer Therapy Market

    = 2002 sales: U.S. $15.4B = Key growth drivers 0 Increased prevalence O Earlier diagnosis 0 Combination therapy O Specialization increasing Sources: Datamontor, Drescher Kleinwort Wasserstein, Stephens, inc, UBS, CSFB Worldwide Cancer Therapy Market Sales (Sbillions) 35 30 4 26 4 & DO Sy Fas US. BEU

  6. Slide 6: Biologics: Strong Growth in Cancer

    Biologics: Stron wth in Cancer = Revenue from monoclonal antibody Oncology Therapy Market Segmentation 2002 products 0 1998: $193.1 million 1 2002: $2.3 billion _ 0 >50% year-on-year growth Hormone 15% Based = Chemotherapy strong ba \ 4 O Targeted therapies = Hormone-based therapies mixed Chemothera

  7. Slide 7: Mission

    Mission Build a competitive, profitable and sustainable oncology business

  8. Slide 8: Oncology Universe market capitalization

    Gricology Universe genayine Market Capitalization (sram 1,000 2° 7,000. a 3,000. cal 2,000. sd an sm: Ann A U5 as Gs Bs as Be ‘ [I 000 itonitoneenoceooe ED 8 BEE cet HSS MS act habe 8 of Ghat oh SF ° ot gp haat GUE Lae OSLO EAE EDIE erate ee s é [iitomparies ith marketed oncology produ

  9. Slide 9: ILEX Oncology Profile

    ILEX Oncology Profile = Focus on development of oncology drugs O Strong franchise with growing product (CAMPATH®) O Promising pipeline with two late-stage products CO First class clinical development organization O Strong scientific resources Locations in Texas, Massachusetts, Switzerland, England 2

  10. Slide 10: Transaction Overview

    jiransact Over' Ww = Stock for stock transaction 0 $26.00/share, collar of $59.88 (0.4342) to $46.58 (0.5582) O ILEX approximately 39M shares outstanding 0 Exchange ratio fixed at time of closing = Expected EPS impact to Genzyme O Excluding amortization, modestly dilutive in near-term O Accretive by

  11. Slide 11: ILEX product pipeline

    CAMPATH - CLL clofarabine — Ped ALL/AML CAMPATH - MS ILX-651 - NSCLC ILX-651 - Melanoma APOMINE CAMPATH - NHL clofarabine - Solid NM3 Preclinical Phase! Phasell_ Phase Ill_ Registration Marketed “

  12. Slide 12: CAMPATH (alemtuzumab for injection)

    GAMPATH® (alemtuzumab for injection) = Marketed since 2001 for B-cell chronic lymphocytic leukemia (B-CLL) O Humanized monoclonal antibody that binds to specific target, CD52, on cell surfaces O Directs immune system to destroy malignant cells = Co-promote with Schering AG/Berlex in U.S. = Only appr

  13. Slide 13: CAMPATH trials initiated

    AMPATH C Siials Initiated = Phase 3: CAMPATH with chlorambucil in B-CLL O Establish first-line use, 300-patient trial to enroll in 2004 = Phase 3: combination therapy 0 CAMPATH and one of most commonly used agents for CLL = Phase 1-2: mono- and combination therapy O CAMPATH alone and with Rituxan® i

  14. Slide 14: Clofarabine

    Glofarabine = Small molecule purine nucleoside analog = Investigating use in pediatric and adult acute leukemia, solid tumors = Initiated rolling New Drug Application (NDA) with FDA for treatment of refractory/relapsed acute pediatric leukemia O Received fast-track designation = Exclusive U.S. and C

  15. Slide 15: ILX-651

    65 = Orally available synthetic analog of natural substance dolastatin with unique mechanism of action targeting tubulin = Currently enrolling Phase II trials in melanoma and non-small cell lung cancer O Demonstrated significant activity against taxane-resistant tumors in animal models = Exclusive w

  16. Slide 16: Early-Stage Pipeline

    tage Pipeline gemyne = APOMINE, Phase II for osteoporosis O Bisphosphonate ester that treats osteoclasts and bone metastasis = NM-3, Phase | commenced in solid tumors O Oral angiogenesis inhibitor = Two preclinical programs in solid tumors O Developmental protein/peptide-based products that target M

  17. Slide 17: Elements of Infrastructure

    Elements of Infrastructure Preclinical Research Discovery 5 —. a \ : . \ Pivotal SN Regulatory’ SSS. imanufacturin Sales and Development,” Reimbursement 7 ™ 9 7 Marketing x fo A jf ft A 7

  18. Slide 18: Genzyme Oncology Today

    Genzyme Oncology Today Mid-Stage Development, + TAPS * TEM Ab + Fusion Vaccine + PRL3 + Polyamines + DENSPM + TEM Sm + TGF-B Ab \ Pivotal <\ Regulatory! “Development Reimbursement “sales and Marketing ‘> Manufacturing > 18

  19. Slide 19: Genzyme Oncology Combined with ILEX

    Genzyme Oncology Gembined with ILEX § Mid-Stage Development + TAPS + TEM Ab + Fusion Vaccine + ILX651 + PRL3 + Polyamines + DENSPM + TEM Sm * TGF-B Ab Pivotal ~~ Regulatoryh > ; Sales and Development Reimbursement (Seta sete sail bes) Marketing + Clofarabine + 2NDAs + Campath in 2007 + 12 MSLs 19

  20. Slide 20: Creating one of the most important oncology franchises

    With this transaction, Genzyme is creating one of the most important oncology franchises in biotechnology 20

  21. Slide 21: Searchable text section of graphics

    Searchable text section of graphics shown above [ LOG O] ILEX TM Oncology, Inc. HOPE INTO REALITY ® [Four photographs depicting (1) two scientists/technicians in lab coats studying chart; (2) fluid measurement instruments; (3) woman kissing infant; and (4) adolescent female patient and woman smiling

Ilex Oncology — Merger or Acquisition (March 2004) on 6ix